Praxis Precision Medicines, Inc. (PRAX) shares ended the last trading session 8.4% higher at $66.30. The jump came on an impressive volume with a higher-than-average number of shares changing ...

Praxis Precision Medicines, Inc. PRAX reported a loss for the second quarter on Tuesday. The company posted a quarterly loss of $1.74 per share which beat the analyst consensus estimate for a ...

Fintel reports that on May 7, 2025, Chardan Capital initiated coverage of Praxis Precision Medicines (NasdaqGS:PRAX) with a Buy recommendation. Analyst Price Forecast Suggests 138.40% Upside As of ...

Praxis Precision Medicines Stock Up 0.8 % Shares of NASDAQ PRAX opened at $38.35 on Friday. The stock has a market capitalization of $781.15 million, a P/E ratio of -3.72 and a beta of 2.65. The ...

Below is a chart showing HOG's trailing twelve month trading history, with the $27 strike highlighted in orange: Praxis Precision Medicines Inc (Symbol: PRAX) options are showing a volume of 1,769 ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor.